Literature DB >> 28246553

The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.

Alan P Skarbnik1, Stefan Faderl2.   

Abstract

Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.

Entities:  

Keywords:  CLL; FCR; chemoimmunotherapy; fludarabine; rituximab

Year:  2016        PMID： 28246553      PMCID： PMC5305006          DOI： 10.1177/2040620716681749

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  34 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Authors:  Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

3.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

4.  Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Jan Burger; Alessandra Ferrajoli; Nitin Jain; Francesco Paolo Tambaro; Zeev Estrov; Jeffrey Jorgensen; Pramoda Challagundla; Stefan H Faderl; William G Wierda
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

5.  Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.

Authors:  M R Grever; K J Kopecky; C A Coltman; J C Files; B R Greenberg; J J Hutton; R Talley; D D Von Hoff; S P Balcerzak
Journal:  Nouv Rev Fr Hematol       Date:  1988

6.  Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia.

Authors:  M J Keating; M Scouros; S Murphy; H Kantarjian; J Hester; K B McCredie; E M Hersh; E J Freireich
Journal:  Leukemia       Date:  1988-03       Impact factor: 11.528

Review 7.  Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).

Authors:  S Kempin; B J Lee; H T Thaler; B Koziner; S Hecht; T Gee; Z Arlin; C Little; D Straus; L Reich; E Phillips; H Al-Mondhiry; M Dowling; K Mayer; B Clarkson
Journal:  Blood       Date:  1982-11       Impact factor: 22.113

8.  Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.

Authors:  S Alas; B Bonavida; C Emmanouilides
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  9 in total

Review 1.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

2.  Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Pierre Feugier; Thérèse Aurran; Béatrice Mahé; Remi Letestu; Florence Nguyen-Khac; Bruno Cazin; Olivier Tournilhac; Hervé Maisonneuve; Olivier Casasnovas; Alain Delmer; Véronique Leblond; Bruno Royer; Bernadette Corront; Sylvie Chevret; Roselyne Delépine; Sandrine Vaudaux; Eric Van Den Neste; Marie-Christine Béné; Florence Cymbalista; Damien Ross-Weil; Stéphane Leprêtre
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

3.  Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Authors:  J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens
Journal:  Blood Adv       Date:  2019-07-23

4.  Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Authors:  Carmen D Herling; Kevin R Coombes; Axel Benner; Johannes Bloehdorn; Lynn L Barron; Zachary B Abrams; Tadeusz Majewski; Jolanta E Bondaruk; Jasmin Bahlo; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer; Bogdan A Czerniak; Christopher C Oakes; Alessandra Ferrajoli; Michael J Keating; Lynne V Abruzzo
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

5.  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Authors:  John C Byrd; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Paul M Barr; Richard R Furman; Thomas J Kipps; Patrick Thornton; Carol Moreno; Marco Montillo; John M Pagel; Jan A Burger; Jennifer A Woyach; Sandra Dai; Remus Vezan; Danelle F James; Jennifer R Brown
Journal:  Blood       Date:  2019-03-06       Impact factor: 25.476

6.  Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Authors:  Francesc Bosch; Guy Cantin; Agostino Cortelezzi; Wolfgang Knauf; Mourad Tiab; Mehmet Turgut; Andrey Zaritskey; Jean-Louis Merot; Eugen Tausch; Kerstin Trunzer; Susan Robson; Ekaterina Gresko; Sebastian Böttcher; Robin Foà; Stephan Stilgenbauer; Véronique Leblond
Journal:  Leukemia       Date:  2019-08-27       Impact factor: 11.528

7.  Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

Authors:  Lynne V Abruzzo; Carmen D Herling; George A Calin; Christopher Oakes; Lynn L Barron; Haley E Banks; Vikram Katju; Michael J Keating; Kevin R Coombes
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

8.  Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.

Authors:  Véronique Leblond; Melih Aktan; Christelle M Ferra Coll; Caroline Dartigeas; Jens Kisro; Marco Montillo; João Raposo; Jean-Louis Merot; Susan Robson; Ekaterina Gresko; Francesc Bosch; Stephan Stilgenbauer; Robin Foà
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

9.  Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition.

Authors:  John J Wilson; Kin-Hoe Chow; Nathan J Labrie; Jane A Branca; Thomas J Sproule; Bryant R A Perkins; Elise E Wolf; Mauro Costa; Grace Stafford; Christine Rosales; Kevin D Mills; Derry C Roopenian; Muneer G Hasham
Journal:  Cancer Biol Ther       Date:  2018-09-05       Impact factor: 4.742
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.